These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 16406989)

  • 1. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer.
    Crawford ED; Sartor O; Chu F; Perez R; Karlin G; Garrett JS
    J Urol; 2006 Feb; 175(2):533-6. PubMed ID: 16406989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A clinical study of 22.5 mg. La-2550: A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer.
    Chu FM; Jayson M; Dineen MK; Perez R; Harkaway R; Tyler RC
    J Urol; 2002 Sep; 168(3):1199-203. PubMed ID: 12187267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
    Pathak AS; Pacificar JS; Shapiro CE; Williams SG
    J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer.
    Sartor O; Dineen MK; Perez-Marreno R; Chu FM; Carron GJ; Tyler RC
    Urology; 2003 Aug; 62(2):319-23. PubMed ID: 12893343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer.
    Perez-Marreno R; Chu FM; Gleason D; Loizides E; Wachs B; Tyler RC
    Clin Ther; 2002 Nov; 24(11):1902-14. PubMed ID: 12501882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
    Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
    BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
    Koiso K; Akaza H; Naito S; Usami M; Tsukamoto T; Shimazaki J; Kotake T; Yamanaka H; Oohashi Y; Yoshinaka R; Onouchi H; Yokokawa K
    Hinyokika Kiyo; 2002 Dec; 48(12):781-95. PubMed ID: 12613016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy over time of LHRH analogs in the treatment of PCa--a prospective analysis using serum testosterone to determine dosing intervals.
    Greil S; Robinson EA; Singal B; Kleer E
    Urology; 2009 Mar; 73(3):631-4. PubMed ID: 19110301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical effects of a 3-month formulation LH-RH agonist (Zoladex LA 10.8 mg depot) in patients with prostate cancer].
    Kotake T; Akaza H; Usami M; Naito S; Kanetake H; Taguchi T; Tsukagoshi S; Koiso K
    Hinyokika Kiyo; 2001 May; 47(5):349-61. PubMed ID: 11433759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A New Sustained-release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer.
    Shore ND; Guerrero S; Sanahuja RM; Gambús G; Parente A
    Clin Ther; 2019 Mar; 41(3):412-425. PubMed ID: 30929678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study.
    Marberger M; Kaisary AV; Shore ND; Karlin GS; Savulsky C; Mis R; Leuratti C; Germa JR
    Clin Ther; 2010 Apr; 32(4):744-57. PubMed ID: 20435244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
    Koiso K; Yamanaka H; Ito K; Yoshinaka R; Uchida S; Yokokawa K
    Hinyokika Kiyo; 2002 Dec; 48(12):771-9. PubMed ID: 12613015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
    Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I
    BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer.
    Shore ND; Chu F; Moul J; Saltzstein D; Concepcion R; McLane JA; Atkinson S; Yang A; Crawford ED
    BJU Int; 2017 Feb; 119(2):239-244. PubMed ID: 26991743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?
    Cox MC; Scripture CD; Figg WD
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):605-11. PubMed ID: 16111462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
    Appu S; Lawrentschuk N; Grills RJ; Neerhut G
    J Urol; 2005 Jul; 174(1):140-2. PubMed ID: 15947599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America.
    Gittelman M; Pommerville PJ; Persson BE; Jensen JK; Olesen TK;
    J Urol; 2008 Nov; 180(5):1986-92. PubMed ID: 18801505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and clinical efficacy of a new 6-month depot formulation of leuprorelin acetate in patients with prostate cancer in Europe.
    Tunn UW; Wiedey K
    Prostate Cancer Prostatic Dis; 2009; 12(1):83-7. PubMed ID: 19030021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer.
    Ozono S; Ueda T; Hoshi S; Yamaguchi A; Maeda H; Fukuyama Y; Takeda K; Ohashi Y; Tsukamoto T; Naito S; Akaza H
    Jpn J Clin Oncol; 2012 Jun; 42(6):477-84. PubMed ID: 22457321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl.
    Crawford ED; Moul JW; Sartor O; Shore ND
    Expert Opin Drug Metab Toxicol; 2015; 11(9):1465-74. PubMed ID: 26293510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.